Organization (Academic)
Vilnius University
ClinicalTrials.gov lists Vilnius University as lead sponsor of 61 trials. It has 3 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Ervinas.spudys, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Vilnius University: 61 lead-sponsored trials and 1 legal-entity registration.
Disease areas (71)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 5 |
| Premature Birth | 5 |
| Anxiety Disorders | 4 |
| Heart Failure | 3 |
| Hemorrhage | 3 |
Showing 5 of 71 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 10 |
| 2020 | 4 |
| 2019 | 10 |
| 2018 | 5 |
| 2017 | 7 |
Showing 10 of 19 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 31 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy | Peritoneal Neoplasms | Not reported | 1 |
| Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy | Stomach Neoplasms | Not reported | 1 |
| Intervention Group | Stress Disorders, Post-Traumatic | Not reported | 1 |
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| (R,S)-ketamine (Pilot I) | 1 |
| Ivabradine | 1 |
| NALTREXONE | 1 |
| CLONIDINE | 1 |
| Lorazepam | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 24% hit target (n=21) | 55% on time (n=20) |
Journals published in (79)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| European journal of heart failure | 12 |
| Journal of the American College of Cardiology | 6 |
| International journal of cardiology | 5 |
| Trials | 5 |
| European heart journal | 4 |
Showing 5 of 79 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 35 | 17 | 2025-07-15 |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Vittore Buzzi Children's Hospital | Co sponsors trial with | 1 |
| Vilnius University Hospital Santaros Klinikos | Co sponsors trial with | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Co sponsors trial with | 1 |
| Ospedale F. Del Ponte, Varese | Co sponsors trial with | 1 |
| Hospital San Pietro Fatebenefratelli | Co sponsors trial with | 1 |
Latest dated events (108)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 108 events.
Biomarker capability evidence (15)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
| MS4A1 | Trial sponsor | Named in trial inclusion criteria |
| MYRF | Trial collaborator | Named in trial inclusion criteria |
| TNNT1 | Trial collaborator | Named in trial inclusion criteria |
| TNNT1 | Trial collaborator | Primary endpoint in a Phase 3 trial |
Showing 5 of 15 evidence rows.
Biomarkers this organization publishes on (401)
Shown in this order: most publications first.
Showing 5 of 401 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.